Clinical Report: Endotype-driven Classification, Diagnosis, and Targeted Treatment of Functional Coronary Vascular Disease
Background
Angina and exertional dyspnea are common symptoms of coronary artery disease (CAD), often linked to obstructive lesions. However, a significant number of patients experience these symptoms despite having non-obstructive coronary arteries, highlighting the need for better understanding and management of ANOCA and INOCA. These conditions can lead to severe complications, including myocardial infarction and ischemic cardiomyopathy.
Data Highlights
No numerical data provided in the source material.
Key Findings
Up to 70% of patients referred for elective coronary angiography due to angina may have ANOCA.
ANOCA can progress to INOCA, MINOCA, and ischemic cardiomyopathy.
Endothelial dysfunction and impaired vasodilation are key pathophysiological mechanisms in ANOCA and INOCA.
Targeted therapies, including calcium channel blockers and nitrates, are essential for managing these conditions.
Early recognition and mechanism-specific therapies are crucial for improving prognosis in patients with ANOCA and INOCA.
Clinical Implications
Healthcare providers should consider endotype-driven diagnostic approaches for patients presenting with angina and non-obstructive coronary arteries. Implementing targeted therapies based on identified endotypes can enhance symptom management and reduce cardiovascular risks.
Conclusion
Endotype-guided strategies are vital for optimizing treatment in patients with ANOCA and INOCA, aiming to improve patient outcomes and prevent disease progression.
Combined rheumatoid factor and anticitrullinated protein antibody status appeared to modify the association between baseline rheumatoid arthritis disease activity and subsequent cardiovascular events in an international observational cohort.
